Intrapleural instillation of interferon γ in patients with malignant pleurisy due to lung cancer

1997 ◽  
Vol 45 (2) ◽  
pp. 93-99 ◽  
Author(s):  
H. Yanagawa ◽  
Takashi Haku ◽  
Keiji Hiramatsu ◽  
Hiroshi Nokihara ◽  
Eiji Takeuchi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interferon Γ ◽  
Malignant Pleurisy

Direct IFNluence of interferon-γ on proliferation and cell-surface antigen expression of non-small cell lung cancer cells

Lung Cancer ◽  
2000 ◽  
Vol 30 (3) ◽  
pp. 169-174 ◽  
Author(s):  
Tokujiro Yano ◽  
Kenji Sugio ◽  
Koji Yamazaki ◽  
Shinichiro Kase ◽  
Masafumi Yamaguchi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Surface ◽  
Small Cell Lung Cancer ◽  
Cancer Cells ◽  
Surface Antigen ◽  
Antigen Expression ◽  
Interferon Γ ◽  
Small Cell ◽  
Small Cell Lung ◽  
Surface Antigen Expression

Effect of postoperative intrapleural instillations of interleukin-2 in patients with malignant pleurisy due to lung cancer

Biotherapy ◽  
1993 ◽  
Vol 6 (2) ◽  
pp. 133-138 ◽  
Author(s):  
Kosei Yasumoto ◽  
Akira Nagashima ◽  
Hisashi Nakahashi ◽  
Teruyoshi Ishida ◽  
Keizo Sugimachi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interleukin 2 ◽  
Malignant Pleurisy

Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 3027-3027
Author(s):  
B. Acres ◽  
E. Quoix ◽  
R. Ramlau ◽  
G. Lacoste ◽  
B. Marie Bastien ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Outcome ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Specific Binding ◽  
Interferon Γ ◽  
Small Cell ◽  
Small Cell Lung ◽  
Color Flow ◽  
Blood Samples

3027 Background: TG4010 is a targeted immunotherapy product. It was tested in combination with first-line chemotherapy in a randomized, controlled, multicenter phase II study in patients with advanced non small cell lung cancer (NSCLC) (ASCO 2008- Abstract No 8023) Methods: In addition to clinical endpoints, immune parameters were tested. Blood samples were drawn prior to therapy (day1) as well as at day 43 (after 6 injections of TG4010). Lymphocyte populations were assessed by 5-color flow cytometry. Plasma samples were tested for biochemical markers using multi-analyte profile technology. Results: Out of the 148 patients enrolled in the study, 138 were evaluable for immunological analyses. Baseline characteristics were similar in both arms. Day 1 blood samples show: i) a correlation between lower levels of inflammation-associated plasma proteins and a longer median survival in Arm 1 (TG4010 + chemotherapy) (p< 0.001); ii) an improved clinical outcome with TG4010 in patients having normal levels of lymphocytes with an activated NK phenotype. Day 43 blood samples show: i) an association between higher levels of activated T lymphocytes and longer patient survival in Arm 1 (p < 0.05). No such association was observed in patients in Arm 2 (chemotherapy alone); ii) a longer survival for patients with higher levels of Interferon γ in Arm 1 than in Arm 2 (p=0.0001). Patients in both Arm 1 and Arm 2 showed specific binding of MUC1 tetramers to circulating CD8+ lymphocytes. No significant association between either treatment arm or clinical outcome and MUC1 tetramer binding was detected. Conclusions: These results identify the level of activated NK cells at baseline as a predictive biomarker for selection of patients to be treated with TG4010. Biomarker data including Interferon γ support a Th1 dependent pathway of activity for TG4010. [Table: see text] [Table: see text]

scholarly journals A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapy

2010 ◽  
Vol 101 (11) ◽  
pp. 2333-2340 ◽  
Author(s):  
Kohsuke Okita ◽  
Shinichiro Motohashi ◽  
Ryo Shinnakasu ◽  
Kaoru Nagato ◽  
Kazuki Yamasaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dendritic Cell ◽  
Cell Therapy ◽  
Cancer Patients ◽  
Interferon Γ ◽  
Lung Cancer Patients ◽  
Dendritic Cell Therapy

The predictive value of the interferon-γ release assay for chemotherapy responses in patients with advanced non-small-cell lung cancer

Lung Cancer ◽  
2018 ◽  
Vol 115 ◽  
pp. 64-70 ◽  
Author(s):  
Hsu-Ching Huang ◽  
Wei-Juin Su ◽  
Chi-Lu Chiang ◽  
Jia-Yih Feng ◽  
Hsin-Yi Huang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Predictive Value ◽  
Interferon Γ ◽  
Small Cell ◽  
Small Cell Lung ◽  
Release Assay

IL-12-induced production of IL-10 and interferon-γ by mononuclear cells in lung cancer-associated malignant pleural effusions

Lung Cancer ◽  
2002 ◽  
Vol 35 (2) ◽  
pp. 171-177 ◽  
Author(s):  
Eiji Takeuchi ◽  
Hiroaki Yanagawa ◽  
Yoshihiro Suzuki ◽  
Kunihiro Shinkawa ◽  
Yasukazu Ohmoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Mononuclear Cells ◽  
Interferon Γ ◽  
Pleural Effusions ◽  
Malignant Pleural Effusions

scholarly journals Malignant Pleurisy Associated with Primary Lung Cancer Well Controlled by Pleurodesis Using Distilled Water

2009 ◽  
Vol 48 (12) ◽  
pp. 1051-1055
Author(s):  
Mitsuaki Sekiya ◽  
Toshiji Ishiwata ◽  
Kaku Yoshimi ◽  
Tetsutaro Nagaoka ◽  
Yoshiteru Morio ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Primary Lung Cancer ◽  
Distilled Water ◽  
Malignant Pleurisy

High concentration of Dezocine induces immune escape of lung cancer and promotes glucose metabolism through up-regulating PD-L1 and activating NF-κB pathway

2021 ◽  
Vol 22 ◽  
Author(s):  
Weiping Dong ◽  
Dong Zhang ◽  
Aiyun Zhu ◽  
Yanli Hu ◽  
Wei Li
Keyword(s):  
Lung Cancer ◽  
Cell Proliferation ◽  
Glucose Metabolism ◽  
Immune Escape ◽  
Opioid Analgesic ◽  
Nuclear Factor Κb ◽  
Interferon Γ ◽  
High Concentration ◽  
Enhanced Production ◽  
Ifn Γ

Background: Dezocine is an opioid analgesic that can affect the immune system. Here, we explored the synergy of high concentration of Dezocine and Programmed death-ligand 1 (PD-L1) with regards to immune escape and glucose metabolism in lung cancer (LC). Methods: PD-L1 level in human LC cell lines was determined and the influence of Dezocine at different concentrations for the proliferation of LC cells was identified. Next, LC cells were transfected to alter PD-L1 level, and exposed to Dezocine at 8 μg/mL to explore their effects on cell proliferation, production of interferon-γ (IFN-γ), contents of glucose, lactate and NADPH/NADP+ and activation of the nuclear factor-κB (NF-κB) pathway. Results: PD-L1 level was increased in LC cells and Dezocine (8 μg/mL) impaired the proliferation of LC cells. Down-regulating PD-L1 inhibited cell proliferation, enhanced production of IFN-γ and reduced the contents of glucose, lactate and NADPH/NADP+ while up-regulating PD-L1 caused the opposite results. Dezocine (8 μg/mL) induced immune escape and glucose metabolism in LC, and Dezocine-induced effects were reversed by down-regulating PD-L1. Dezocine (8 μg/mL) up-regulated PD-L1 by activating the NF-κB pathway. Conclusion: Dezocine at 8 μg/mL promotes immune escape and glucose metabolism in LC through up-regulating PD-L1 and activating the NF-κB pathway.

Sign in / Sign up

Export Citation Format

Share Document